The Phase 3 trial which aims at over all survival, is a double-blind, randomized trial involved around 430 patients to compare the safety and efficacy of perifosine + capecitabine vs. placebo + capecitabine inrefractory advanced colorectal cancer.
Keryx CEO Ron Bentsur said they believe that the rapid enrollment into the study, of less than 16 months in US centers only, reinforces the need for additional therapies for the tens of thousands of patients suffering from refractory, advanced colorectal cancer.